

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028

<https://marketpublishers.com/r/PAE67260F92EN.html>

Date: November 2023

Pages: 196

Price: US\$ 4,950.00 (Single User License)

ID: PAE67260F92EN

Abstracts

The global particle therapy market is projected to reach USD 1.1 billion by 2028 from USD 0.7 billion in 2023, growing at a CAGR of 8.2% during the forecast period. The projected surge in market growth for the Particle therapy market is seen due to an increase in cancers, advancements in technologies, and increased awareness among individuals regarding cancer, Increased funding for cancer research.

“The Paediatric application segment to register highest CAGR over the forecast period of 2023-2028.”

Based on the cancer type, the Particle therapy market is segmented into pediatric cancer, breast cancer, lung cancer, prostate cancer, head and neck, and other cancers. Pediatric cancer has witnessed the highest growth rate In 2022. The increase in Paediatric cancers can be seen due to the following reasons genetic predisposition, developmental factors in infants, immature immune system, environmental exposures, maternal factors, and cellular vulnerability among others.

“Asia Pacific to register significant growth rate in the market during the forecast period.”

For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises

India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for the particle therapy market. There are several drivers that contributed to this growth:

The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of the Particle therapy market substantiates its pivotal role in enhancing the market landscape.

The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like the Particle therapy market, confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region's desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of particle therapy market.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%

By Designation: C-level–27%, Director-level–18%, and Others–55%

By Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Prominent players in particle therapy market are Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) among others.

Research Coverage

The report studies the Particle therapy market based on type, system, product, application, cancer type and region.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.

The report studies micro markets with respect to their growth trends, prospects, and contributions to the global Particle therapy market.

The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Particle therapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:

Analysis of key drivers (increasing prevalence of cancer patient population, Increasing government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of particle therapy, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the Particle therapy market

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the particle therapy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the Particle therapy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Particle therapy market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) among others.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.3 INCLUSIONS & EXCLUSIONS

1.4 MARKET SCOPE

1.4.1 MARKETS COVERED

1.4.2 REGIONS COVERED

1.4.3 YEARS CONSIDERED

1.4.4 CURRENCY CONSIDERED

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

2.1.2.1 Key primary sources

2.1.2.2 Key data from primary sources

2.1.2.3 Breakdown of primaries

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION

2.1.2.4 Key industry insights

2.2 MARKET SIZE ESTIMATION

FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022

FIGURE 5 SUPPLY-SIDE ANALYSIS

FIGURE 6 TOP-DOWN APPROACH

FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 8 CAGR PROJECTIONS

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 9 DATA TRIANGULATION METHODOLOGY

2.4 RESEARCH LIMITATIONS

2.4.1 SCOPE-RELATED LIMITATIONS

2.4.2 METHODOLOGY-RELATED LIMITATIONS

2.5 RISK ASSESSMENT

2.6 STUDY ASSUMPTIONS

2.6.1 IMPACT OF RECESSION ON PARTICLE THERAPY MARKET

3 EXECUTIVE SUMMARY

FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)

FIGURE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION)

FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET

4 PREMIUM INSIGHTS

4.1 PARTICLE THERAPY MARKET OVERVIEW

FIGURE 17 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET

4.2 REGIONAL MIX: PARTICLE THERAPY MARKET

FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD

4.3 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022)

FIGURE 19 PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022

4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

4.5 DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET

FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING

FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

FIGURE 22 PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.1.1 DRIVERS

- 5.1.1.1 Advantages of particle therapy over photon therapy
- 5.1.1.2 Growing prevalence of cancer
- 5.1.1.3 Rising adoption of particle therapy in clinical trials
- 5.1.1.4 Increasing number of particle therapy centers worldwide
- 5.1.1.5 Technological advancements

5.1.2 RESTRAINTS

- 5.1.2.1 Infrastructural challenges in healthcare facilities
- 5.1.2.2 Affordability and accessibility of treatments
- 5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy

5.1.3 OPPORTUNITIES

- 5.1.3.1 Growth potential of emerging economies

5.1.4 CHALLENGES

- 5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures
- 5.1.4.2 Potential for unwanted radiation exposure

5.2 ECOSYSTEM/MARKET MAP

FIGURE 23 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS

5.3 PRICING ANALYSIS

5.4 SUPPLY CHAIN ANALYSIS

FIGURE 24 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET

5.5 PATENT ANALYSIS

5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET

FIGURE 25 TOTAL PATENTS GRANTED FROM 2012–2022

FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY

FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY

5.6 VALUE CHAIN ANALYSIS

FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS

5.7 TECHNOLOGY ANALYSIS

5.8 KEY CONFERENCES & EVENTS IN 2023–2024

5.9 REGULATORY LANDSCAPE

TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT

AGENCIES, AND OTHER ORGANIZATIONS

TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION

5.10 REIMBURSEMENT ANALYSIS

TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022

5.11 TRADE ANALYSIS

TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES

5.12 PORTER'S FIVE FORCES ANALYSIS

TABLE 9 PARTICLE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS

5.12.1 THREAT OF NEW ENTRANTS

5.12.2 THREAT OF SUBSTITUTES

5.12.3 BARGAINING POWER OF SUPPLIERS

5.12.4 BARGAINING POWER OF BUYERS

5.12.5 DEGREE OF COMPETITION

5.13 KEY STAKEHOLDERS & BUYING CRITERIA

5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS

TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%)

5.13.2 BUYING CRITERIA

FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS

TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS

5.14 CASE STUDY ANALYSIS

TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY—RT'S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC)

5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX

6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION

TABLE 13 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028
(USD MILLION)

6.2 PRODUCTS

TABLE 14 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD
MILLION)

TABLE 15 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028
(USD MILLION)

6.2.1 CYCLOTRONS

6.2.1.1 Advantages offered by cyclotrons over other accelerators to drive market

TABLE 16 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 17 NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 18 EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 19 ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 20 LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

6.2.2 SYNCHROTRONS

6.2.2.1 Increasing investments for development of synchrotron facilities to aid market
growth

TABLE 21 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 22 NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY,
2021–2028 (USD MILLION)

TABLE 23 EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 24 ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 25 LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

6.2.3 SYNCHROCYCLOTRONS

6.2.3.1 High space requirements to limit adoption

TABLE 26 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD
MILLION)

TABLE 27 NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY,
2021–2028 (USD MILLION)

TABLE 28 EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028

(USD MILLION)

TABLE 29 ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 30 LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

6.3 SERVICES

6.3.1 AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET

TABLE 31 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 32 NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 33 EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 34 ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 35 LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

7 PARTICLE THERAPY MARKET, BY TYPE

7.1 INTRODUCTION

TABLE 36 PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)

7.2 PROTON THERAPY

7.2.1 GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET

TABLE 37 PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)

7.3 HEAVY ION THERAPY

7.3.1 SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS

TABLE 38 HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)

8 PARTICLE THERAPY MARKET, BY SYSTEM

8.1 INTRODUCTION

TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)

8.2 MULTI-ROOM SYSTEMS

8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS

TABLE 40 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY

REGION, 2021–2028 (USD MILLION)

8.3 SINGLE-ROOM SYSTEMS

8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH

TABLE 41 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION)

9 PARTICLE THERAPY MARKET, BY APPLICATION

9.1 INTRODUCTION

TABLE 42 PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

9.2 TREATMENT APPLICATIONS

9.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH

TABLE 43 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)

9.3 RESEARCH APPLICATIONS

9.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES

TABLE 44 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)

10 PARTICLE THERAPY MARKET, BY CANCER TYPE

10.1 INTRODUCTION

TABLE 45 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)

10.2 PEDIATRIC CANCER

10.2.1 INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET

TABLE 46 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION)

10.3 PROSTATE CANCER

10.3.1 ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET

TABLE 47 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)

10.4 LUNG CANCER

10.4.1 GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG

CANCER TO DRIVE MARKET

TABLE 48 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION,
2021–2028 (USD MILLION)

10.5 BREAST CANCER

10.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO
INCREASE ADOPTION OF PARTICLE THERAPY

TABLE 49 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION,
2021–2028 (USD MILLION)

10.6 HEAD & NECK CANCER

10.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT
MARKET GROWTH

TABLE 50 PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY
REGION, 2021–2028 (USD MILLION)

10.7 OTHER CANCERS

TABLE 51 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION,
2021–2028 (USD MILLION)

11 PARTICLE THERAPY MARKET, BY REGION

11.1 INTRODUCTION

TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)

11.2 NORTH AMERICA

11.2.1 NORTH AMERICA: RECESSION IMPACT

FIGURE 32 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT

TABLE 53 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY,
2021–2028 (USD MILLION)

TABLE 54 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028
(USD MILLION)

TABLE 55 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT &
SERVICE, 2021–2028 (USD MILLION)

TABLE 56 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY
TYPE, 2021–2028 (USD MILLION)

TABLE 57 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM,
2021–2028 (USD MILLION)

TABLE 58 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2021–2028 (USD MILLION)

TABLE 59 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION,
2021–2028 (USD MILLION)

11.2.2 US

11.2.2.1 Growing number of particle therapy centers to drive market growth

TABLE 60 US: MACROECONOMIC INDICATORS

TABLE 61 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 62 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028
(USD MILLION)

11.2.3 CANADA

11.2.3.1 Government initiative to include particle therapy as treatment method to
boost market

TABLE 63 CANADA: MACROECONOMIC INDICATORS

TABLE 64 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 65 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

11.3 EUROPE

11.3.1 EUROPE: RECESSION IMPACT

TABLE 66 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 67 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD
MILLION)

TABLE 68 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 69 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

TABLE 70 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD
MILLION)

TABLE 71 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028
(USD MILLION)

TABLE 72 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028
(USD MILLION)

11.3.2 GERMANY

11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth

TABLE 73 GERMANY: MACROECONOMIC INDICATORS

TABLE 74 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 75 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

11.3.3 FRANCE

11.3.3.1 Increasing healthcare expenditure to support particle therapy product

adoption

TABLE 76 FRANCE: MACROECONOMIC INDICATORS

TABLE 77 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 78 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

11.3.4 UK

11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to
support market growth

TABLE 79 UK: MACROECONOMIC INDICATORS

TABLE 80 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 81 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028
(USD MILLION)

11.3.5 ITALY

11.3.5.1 Increasing awareness activities to support market growth

TABLE 82 ITALY: MACROECONOMIC INDICATORS

TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 84 ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028
(USD MILLION)

11.3.6 SPAIN

11.3.6.1 Increasing number of conferences and government funding for cancer
research to drive market

TABLE 85 SPAIN: MACROECONOMIC INDICATORS

TABLE 86 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 87 SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028
(USD MILLION)

11.3.7 REST OF EUROPE

TABLE 88 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT &
SERVICE, 2021–2028 (USD MILLION)

TABLE 89 REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY
TYPE, 2021–2028 (USD MILLION)

11.4 ASIA PACIFIC

11.4.1 ASIA PACIFIC: RECESSION IMPACT

FIGURE 33 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT

TABLE 90 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 91 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028
(USD MILLION)

TABLE 92 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT &
SERVICE, 2021–2028 (USD MILLION)

TABLE 93 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

TABLE 94 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028
(USD MILLION)

TABLE 95 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2021–2028 (USD MILLION)

TABLE 96 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION,
2021–2028 (USD MILLION)

11.4.2 JAPAN

11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market

TABLE 97 JAPAN: MACROECONOMIC INDICATORS

TABLE 98 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 99 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

11.4.3 CHINA

11.4.3.1 High cancer burden to drive market

TABLE 100 CHINA: MACROECONOMIC INDICATORS

TABLE 101 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 102 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

11.4.4 INDIA

11.4.4.1 Improving research capabilities to support market growth

TABLE 103 INDIA: MACROECONOMIC INDICATORS

TABLE 104 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 105 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2021–2028 (USD MILLION)

11.4.5 AUSTRALIA

11.4.5.1 Healthcare funding availability to boost market growth

TABLE 106 AUSTRALIA: MACROECONOMIC INDICATORS

TABLE 107 AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION)

TABLE 108 AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,

2021–2028 (USD MILLION)

11.4.6 SOUTH KOREA

11.4.6.1 Rising prevalence of cancer to drive market

TABLE 109 SOUTH KOREA: MACROECONOMIC INDICATORS

TABLE 110 SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 111 SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

11.4.7 REST OF ASIA PACIFIC

TABLE 112 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 113 REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

11.5 LATIN AMERICA

11.5.1 LATIN AMERICA: RECESSION IMPACT

TABLE 114 LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 115 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 116 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 117 LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 118 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)

TABLE 119 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)

TABLE 120 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

11.5.2 BRAZIL

11.5.2.1 Government initiatives to propel market growth

TABLE 121 BRAZIL: MACROECONOMIC INDICATORS

TABLE 122 BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 123 BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

11.5.3 MEXICO

11.5.3.1 Growing adoption of advanced medical technologies to drive market

TABLE 124 MEXICO: MACROECONOMIC INDICATORS

TABLE 125 MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 126 MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

11.5.4 REST OF LATIN AMERICA

TABLE 127 REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 128 REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

11.6 MIDDLE EAST & AFRICA

11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET

11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

TABLE 129 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 130 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)

TABLE 131 MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 132 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)

TABLE 133 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)

TABLE 134 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 STRATEGIES ADOPTED BY KEY PLAYERS

FIGURE 34 KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET

12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS

FIGURE 35 REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET

12.4 MARKET SHARE ANALYSIS

FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022

12.5 COMPANY EVALUATION MATRIX

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

FIGURE 37 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022

12.6 COMPETITIVE BENCHMARKING FOR KEY PLAYERS

12.6.1 PARTICLE THERAPY MARKET: COMPANY FOOTPRINT

TABLE 135 OVERALL COMPANY FOOTPRINT (10 COMPANIES)

TABLE 136 TYPE FOOTPRINT (10 COMPANIES)

TABLE 137 PRODUCT & SERVICE FOOTPRINT (10 COMPANIES)

TABLE 138 SYSTEM FOOTPRINT (10 COMPANIES)

TABLE 139 CANCER TYPE FOOTPRINT (10 COMPANIES)

TABLE 140 APPLICATION FOOTPRINT (10 COMPANIES)

TABLE 141 REGIONAL FOOTPRINT (10 COMPANIES)

12.7 STARTUP/SME EVALUATION MATRIX

12.7.1 PROGRESSIVE COMPANIES

12.7.2 RESPONSIVE COMPANIES

12.7.3 DYNAMIC COMPANIES

12.7.4 STARTING BLOCKS

FIGURE 38 PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022

12.7.5 COMPETITIVE BENCHMARKING FOR STARTUPS/SMES

TABLE 142 OVERALL COMPANY FOOTPRINT

TABLE 143 TYPE FOOTPRINT

TABLE 144 PRODUCT & SERVICE FOOTPRINT

TABLE 145 SYSTEM FOOTPRINT

TABLE 146 CANCER TYPE FOOTPRINT

TABLE 147 APPLICATION FOOTPRINT

TABLE 148 REGIONAL FOOTPRINT

12.8 COMPETITIVE SCENARIOS & TRENDS

12.8.1 PRODUCT LAUNCHES & APPROVALS

TABLE 149 PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?AUGUST 2023)

12.8.2 DEALS

TABLE 150 PARTICLE THERAPY MARKET: DEALS (JANUARY 2020?AUGUST 2023)

12.8.3 OTHER DEVELOPMENTS

TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020?AUGUST 2023)

13 COMPANY PROFILES

13.1 KEY PLAYERS

(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*

13.1.1 IBA WORLDWIDE

TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW

FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022)

13.1.2 VARIAN MEDICAL SYSTEMS, INC.

TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW

FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)

13.1.3 HITACHI, LTD.

TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW

FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021)

13.1.4 MEVION MEDICAL SYSTEMS

TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW

13.1.5 SUMITOMO HEAVY INDUSTRIES LTD.

TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW

FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)

13.1.6 PROVISION HEALTHCARE, LLC

TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW

13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION

TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW

FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022)

13.1.8 OPTIVUS PROTON THERAPY, INC.

TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW

13.1.9 PROTOM INTERNATIONAL, INC.

TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW

13.1.10 ADVANCED ONCOTHERAPY PLC

TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW

13.2 OTHER PLAYERS

13.2.1 DANFYSIK A/S

TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW

13.2.2 P-CURE, LTD.

TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW

13.2.3 PTW FREIBURG GMBH

TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats,

Recent Developments might not be captured in case of unlisted companies.

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

I would like to order

Product name: Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/PAE67260F92EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PAE67260F92EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970